A small Life Sciences organization had an established product in the Oral CGRP market focused on acute treatment of migraines.
Fifteen months post launch, the brand received an additional indication for the preventative treatment of episodic migraines.
Propensity4 was able to deliver a final targeting scheme in 8 weeks, marrying primary and secondary data to create an informed targeting approach.
The brand was able to deliver 4x the forecast across both indications in a highly genericized market.
Jump to a slide with the slide dots.
End-to-end US launch support for EU client’s dry eye device—from KAM team and CRM setup to data analytics, targeting, and incentive strategy.
Read more
This blog explores how “bottom-up” forecasting, particularly Most Probable Forecasting (MPF), enhances pharmaceutical brand planning.
Read more
Personalized patient engagement boosted therapy adherence with AI-driven insights, risk scoring, and tailored support recommendations.
Read more
Accelerating rare disease diagnosis through data-driven patient finding and predictive modeling to connect patients with the right HCPs faster.
Read more
Propensity4 reduced field target lists by 97% with a dynamic targeting framework that improved prioritization and protected KPI performance.
Read more